Allergan Plc (AGN)

166.47
NYSE : Health Technology
Prev Close 165.73
Day Low/High 165.42 / 167.29
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.73M
Exchange NYSE
Shares Outstanding 328.10M
Market Cap 54.38B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)
Allergan To Present VRAYLAR® (cariprazine) Data At The American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment To Mental Health

Allergan To Present VRAYLAR® (cariprazine) Data At The American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment To Mental Health

Abstracts will showcase research on VRAYLAR, including a focus on an investigational use for the treatment of bipolar depression

PatientFi® Announces Study Partnership With Allergan

PatientFi® Announces Study Partnership With Allergan

PatientFi, LLC, a leading financial technology company that partners with medical practices to offer patients accessible financing plans for elective procedures, is pleased to announce its partnership with Allergan plc on a year-long market research study...

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.

Allergan To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

Allergan To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

DUBLIN, May 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada.

Dow Falls Nearly 500 Points as U.S.-China Trade Talk Fears Return

Dow Falls Nearly 500 Points as U.S.-China Trade Talk Fears Return

Stocks end down sharply as markets react to latest twists in trade spat between the U.S. and China.

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?

Allergan Tops Q1 Earnings Estimate, Boosts Full-Year Profit Outlook

Allergan Tops Q1 Earnings Estimate, Boosts Full-Year Profit Outlook

Allergan posted stronger-than-expected first quarter earnings Tuesday, and boosted its full-year profit guidance, as Botox sales continue to drive top-line growth for the Dublin-based pharmaceutical group.

Allergan Stock Slips Despite Beat and Raised Guidance

Allergan Stock Slips Despite Beat and Raised Guidance

Shares of the maker of Botox are struggling despite its latest results exceeding expectations.

Global Stocks Drift As China Confirms Trade Participation, US Warns on Tariffs

Global Stocks Drift As China Confirms Trade Participation, US Warns on Tariffs

Global stocks were mixed higher Tuesday, while U.S. equity futures drifted modestly into the red, as investors kept risk appetite in check ahead of a key series of trade talks between Washington and Beijing later this week that could define or collapse an elusive pact between the world's two largest economies.

Lyft, Anadarko, AIG, AB InBev and Trade Talks - 5 Things You Must Know

Lyft, Anadarko, AIG, AB InBev and Trade Talks - 5 Things You Must Know

U.S. stock futures slump as investors focus on trade talks later this week between Washington and Beijing; Lyft will issue its first earnings report as a public company on Tuesday; Anadarko says it favors Occidental's takeover bid over Chevron's offer.

Allergan Reports First Quarter 2019 Financial Results

Allergan Reports First Quarter 2019 Financial Results

-- Q1 2019 GAAP Net Revenues of $3.60 Billion --

Aegon Calls USD 500 Million In Perpetual Capital Securities

Aegon Calls USD 500 Million In Perpetual Capital Securities

Aegon today announces that it is exercising its right to redeem the USD 500 million perpetual capital securities with a coupon of 6.

Allergan Expected to Earn $3.55 a Share

Allergan Expected to Earn $3.55 a Share

Allergan revenue expected to fall 3.7% to $3.5 billion.

Medicines360 And Allergan Present Six-Year Clinical Data From Largest Ongoing Phase 3 Study Of An Intrauterine System In The U.S.

Medicines360 And Allergan Present Six-Year Clinical Data From Largest Ongoing Phase 3 Study Of An Intrauterine System In The U.S.

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting

Status Quo Great for Stocks: Cramer's 'Mad Money' Recap (Friday 5/3/19)

Status Quo Great for Stocks: Cramer's 'Mad Money' Recap (Friday 5/3/19)

Jim Cramer says the economy is just right for stocks, but he's still worried about IPO froth. Here's your game plan for next week.

Allergan Declares Second Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

Allergan Declares Second Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

- Dividend to be Paid on June 14, 2019 -

Allergan To Present Two Podium Presentations On Bimatoprost Sustained-Release (SR) At The American Society Of Cataract And Refractive Surgery (ASCRS) Annual Meeting

Allergan To Present Two Podium Presentations On Bimatoprost Sustained-Release (SR) At The American Society Of Cataract And Refractive Surgery (ASCRS) Annual Meeting

-New data will provide insights on treatment duration and biodegradation of the experimental implant in patients with open-angle glaucoma or ocular hypertension-

Allergan Continues To Display Leadership In Neurosciences With 29 Presentations At 2019 American Academy Of Neurology Annual Meeting

Allergan Continues To Display Leadership In Neurosciences With 29 Presentations At 2019 American Academy Of Neurology Annual Meeting

- Allergan MIND™, Allergan's migraine franchise, leads meeting with the most migraine presentations: 24 abstracts highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, ubrogepant and atogepant -

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

Jim Cramer says it's not 1987 or 1999, and there's no reason to dump stocks right now, but he does advocate discipline and caution.

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Jim Cramer weighs in on Kohl's, Exxon Mobil, Delta Air Lines, Allergan, Arrowhead Research, Wayfair, Varonis Systems and more.

Allergan Announces Results From The 2019 Annual General Meeting Of Shareholders

Allergan Announces Results From The 2019 Annual General Meeting Of Shareholders

-- Shareholders Approved All Allergan Proposals and Voted AGAINST Shareholder Proposal Calling for Immediate Separation of Chairman and CEO Role --

Breakthrough Tuesday

New highs grow on the New York Stock Exchange and the Investor Intelligence bulls finally tops 55%.

New Study Showcases Economic And Community Impact Of Allergan's Operations In Ohio

New Study Showcases Economic And Community Impact Of Allergan's Operations In Ohio

- Cincinnati facility generates annual economic output of $46.3 million and total earnings of $28.8 million -

Leading Proxy Advisory Firms ISS And Glass Lewis Support ALL Of Allergan Board's Voting Recommendations

Leading Proxy Advisory Firms ISS And Glass Lewis Support ALL Of Allergan Board's Voting Recommendations

- ISS and Glass Lewis Recommend AGAINST Appaloosa's Proposal to Immediately Separate Chair and CEO Roles -

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

- Company Recognized for Continued Superior Energy Achievements -

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

DUBLIN, April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Aegon Publishes Agenda For 2019 Annual General Meeting

Aegon Publishes Agenda For 2019 Annual General Meeting

Today, Aegon N.V.

TheStreet Quant Rating: C (Hold)